Detalhe da pesquisa
1.
Absorption, Metabolism, and Excretion, In Vitro Pharmacology, and Clinical Pharmacokinetics of Ozanimod, a Novel Sphingosine 1-Phosphate Receptor Modulator.
Drug Metab Dispos
; 49(5): 405-419, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33674268
2.
Therapeutic protein-drug interaction assessment for daclizumab high-yield process in patients with multiple sclerosis using a cocktail approach.
Br J Clin Pharmacol
; 82(1): 160-7, 2016 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-26991517
3.
Population PK-PD analyses of CD25 occupancy, CD56bright NK cell expansion, and regulatory T cell reduction by daclizumab HYP in subjects with multiple sclerosis.
Br J Clin Pharmacol
; 82(5): 1333-1342, 2016 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-27333593
4.
Efficacy and safety of danoprevir-ritonavir plus peginterferon alfa-2a-ribavirin in hepatitis C virus genotype 1 prior null responders.
Antimicrob Agents Chemother
; 58(2): 1136-45, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24295986
5.
Two-way interaction study between ritonavir boosted danoprevir, a potent HCV protease inhibitor, and ketoconazole in healthy subjects.
Int J Clin Pharmacol Ther
; 52(2): 103-11, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24290411
6.
Concentration-QTc modeling of sitravatinib in patients with advanced solid malignancies.
Clin Transl Sci
; 17(5): e13808, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38700272
7.
A randomised study of the effect of danoprevir/ritonavir or ritonavir on substrates of cytochrome P450 (CYP) 3A and 2C9 in chronic hepatitis C patients using a drug cocktail.
Eur J Clin Pharmacol
; 69(11): 1939-49, 2013 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-23872824
8.
Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN α-2a/RBV in hepatitis C patients.
J Hepatol
; 55(5): 972-9, 2011 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-21354234
9.
Physiological modeling and assessments of regional drug bioavailability of danoprevir to determine whether a controlled release formulation is feasible.
Biopharm Drug Dispos
; 32(5): 261-75, 2011 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-21660978
10.
Concentration-QTc Modeling of Ozanimod's Major Active Metabolites in Adult Healthy Subjects.
CPT Pharmacometrics Syst Pharmacol
; 10(2): 119-126, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33314790
11.
Single-Dose Pharmacokinetics of Ozanimod and its Major Active Metabolites Alone and in Combination with Gemfibrozil, Itraconazole, or Rifampin in Healthy Subjects: A Randomized, Parallel-Group, Open-Label Study.
Adv Ther
; 37(10): 4381-4395, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32857315
12.
Multiple-Dose Pharmacokinetics of Ozanimod and its Major Active Metabolites and the Pharmacodynamic and Pharmacokinetic Interactions with Pseudoephedrine, a Sympathomimetic Agent, in Healthy Subjects.
Adv Ther
; 37(12): 4944-4958, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33025342
13.
Effect of the sphingosine-1-phosphate receptor modulator ozanimod on leukocyte subtypes in relapsing MS.
Neurol Neuroimmunol Neuroinflamm
; 7(5)2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32737072
14.
Effects of High- and Low-Fat Meals on the Pharmacokinetics of Ozanimod, a Novel Sphingosine-1-Phosphate Receptor Modulator.
Clin Pharmacol Drug Dev
; 7(6): 634-640, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29125718
15.
Cardiac Safety of Ozanimod, a Novel Sphingosine-1-Phosphate Receptor Modulator: Results of a Thorough QT/QTc Study.
Clin Pharmacol Drug Dev
; 7(3): 263-276, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28783871
16.
Results From the First-in-Human Study With Ozanimod, a Novel, Selective Sphingosine-1-Phosphate Receptor Modulator.
J Clin Pharmacol
; 57(8): 988-996, 2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28398597
17.
Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers and Subjects with Multiple Sclerosis: Analysis of Phase I-III Clinical Trials.
Clin Pharmacokinet
; 55(8): 943-55, 2016 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-26873229
18.
Blockade of the High-Affinity Interleukin-2 Receptors with Daclizumab High-Yield Process: Pharmacokinetic/Pharmacodynamic Analysis of Single- and Multiple-Dose Phase I Trials.
Clin Pharmacokinet
; 55(1): 121-30, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26242380
19.
Pharmacokinetics of daclizumab high-yield process with repeated administration of the clinical subcutaneous regimen in patients with relapsing-remitting multiple sclerosis.
Clin Pharmacol
; 8: 9-13, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-26929672
20.
Pharmacokinetic interaction between amprenavir and delavirdine: evidence of induced clearance by amprenavir.
Clin Pharmacol Ther
; 72(6): 615-26, 2002 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-12496743